Resultats de la cerca - Dirk Müeller
- Mostrar 1 - 10 resultats de 10
-
1
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-... per Thomas Langbein, Harshad Kulkarni, Christiane Schuchardt, Dirk Müeller, Gerd Fabian Volk, Richard P. Baum
Publicat 2022Artigo -
2
-
3
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen per Harshad Kulkarni, Aviral Singh, Thomas Langbein, Christiane Schuchardt, Dirk Müeller, Jingjing Zhang, Coline Lehmann, Richard P. Baum
Publicat 2018Revisão -
4
Radiolabeling of DOTA-like conjugated peptides with generator-produced 68Ga and using NaCl-based cationic elution method per Dirk Müeller, Wouter A.P. Breeman, Ingo Klette, Michael Gottschaldt, Andreas Odparlik, M. Baehre, Izabela Tworowska, Michael K. Schultz
Publicat 2016Artigo -
5
Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-a... per Jan Gaertner, Waldemar Siemens, Joerg J Meerpohl, Gerd Antes, Cornelia Meffert, Carola Xander, Stephanie Stock, Dirk Müeller, Guido Schwarzer, Gerhild Becker
Publicat 2017Revisão -
6
<sup>177</sup>Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy per Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt, Aviral Singh, Martina Wirtz, Stefan Wiessalla, Margret Schottelius, Dirk Müeller, Ingo Klette, Hans‐Jürgen Wester
Publicat 2016Artigo -
7
Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities per Desislava Yanakieva, Lukas Pekar, Andreas Evers, Markus Fleischer, Stephan Sylvest Keller, Dirk Mueller-Pompalla, Lars Toleikis, Harald Kolmar, Stefan Zielonka, Simon Krah
Publicat 2022Artigo -
8
Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms per Richard P. Baum, Harshad Kulkarni, Aviral Singh, Daniel Kaemmerer, Dirk Müeller, Vikas Prasad, Merten Hommann, F Robiller, Karin Niepsch, Holger Franz, Arthur Jochems, Philippe Lambin, Dieter Hörsch
Publicat 2018Artigo -
9
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using <sup>177</sup>Lu-FAP-2286: First-in-Humans Results per Richard P. Baum, Christiane Schuchardt, Aviral Singh, Maythinee Chantadisai, F Robiller, Jingjing Zhang, Dirk Müeller, Alexander Eismant, Frankis Almaguel, Dirk Zboralski, Frank Osterkamp, Aileen Hoehne, Ulrich Reineke, Christiane Smerling, Harshad Kulkarni
Publicat 2021Artigo -
10
Hydrocephalus in Amazona aestiva - case report per L.T.S. Hanna, Camila Siqueira Costa, Beatriz Senra Álvares da Silva Santos, Nágila Rocha Aguilar, Karen Yumi Ribeiro Nakagaki, Júlia Gabriela Wronski, A.A. Fernandes, Dirk Müeller, M.C. Ortiz, Maria Isabel Maldonado Coelho Guedes, É.A. Costa, Nélson Rodrigo da Silva Martins
Publicat 2024Artigo
Eines de cerca:
Matèries relacionades
Medicine
Internal medicine
Cancer
Chemistry
Adverse effect
Biology
Immunology
Nuclear medicine
Oncology
Prostate cancer
Radionuclide therapy
Receptor
Antibody
Biochemistry
Cancer research
Chromatography
Gastroenterology
Glutamate carboxypeptidase II
Monoclonal antibody
Organic chemistry
Prostate
Radiochemistry
Radioligand
Urology
Acetone
Antigen
Biodistribution
Bioinformatics
Biotechnology
Bispecific antibody